Publicador de contenidos

Investigación e Innovación Programas
Investigación

Efecto de combinaciones de fármacos y péptidos antibacterianos frente a 'M. tuberculosis' utilizando métodos in vitro y ex vivo. Análisis en fase exponencial y en latencia

Duración
01/01/2017 - 30/03/2017
Financiadores
Ministerio de Ciencia, Innovación y Universidades. Instituto de Salud Carlos III. Unión Europea. Este proyecto está cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). “Una manera de hacer Europa”

Objectives

  1. Determine the synergistic activity of in vitro methods and the efficacy using a human macrophage model (THP-1 cell line) of the following combinations: Levofloxacin+clofazimine+PA-824; quinolone UB-8902 +clofazimine+PA-824; moxifloxacin+clofazimine+PA-8242.
  2. Determine the MIC of a collection of 14 antimicrobial peptides against M tuberculosis.
  3. Study the activity of the peptide and drug combinations of objectives 1 and 2 against clinical strains of M tuberculosis in latency.

 

Methods

We will use 10 multiresistant and 10 susceptible clinical strains of M. tuberculosis. The MIC of individual drugs will be determined using solid culture medium 7H11. The efficacy of the proposed combinations will be analyzed with the chequerboard method using solid culture medium and with the killing curves method, using liquid (7H9) and solid (7H11) culture medium.

Moreover, the combinations will be analyzed in a human macrophage model (THP-1 cell line). In this model the intracellular drug concentrations will be determined. On the other part, the MIC of a collection of 14 antimicrobial peptides will be analyzed, using liquid medium 7H9 and alamar blue reading.

Lastly, the effect of drugs alone and in combination and also the antimicrobial peptides, will be studied in a latency model based on nutrient starvation using PBS as culture medium.

Total Funding

69,575.00 euros

Project Code

PI13/01752

Nuestro equipo

Equipo ISGlobal

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

GAMA

Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

PreFIT

Predicting the Future: Incipient Tuberculosis

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

END-VOC

ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)

TwinAir

Digital Twins Enabled Indoor Air Quality Management for Healthy Living

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias